Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. SEC filings document the company’s operating results, material events and governance as a NYSE-listed construction services issuer. Recent 8-K filings report quarterly and fiscal financial results, cash dividends, share repurchase program actions, and engineering, procurement and construction contract developments involving Gemma Power Systems and power-generation projects.
Proxy materials cover board elections, executive compensation, equity awards, shareholder voting matters and related governance disclosures. The filings also identify Argan’s common stock registration and formal event reporting for capital allocation and project-backlog developments.
ARGAN INC director Karen Sweeney reported an open-market sale of company stock. On June 17, 2026, she sold 300 shares of Argan common stock at a price of $705 per share. After this transaction, she directly holds 1,548 shares of Argan common stock.
ARGAN INC director Peter W. Getsinger reported an option exercise followed by open-market sales of common stock. On June 15, 2026, he exercised a stock option to purchase 5,000 shares at $35.72 per share using the net settle method, resulting in 4,728 shares of common stock.
He then sold 4,728 shares on June 16, 2026 at an average price of $708.65 per share and 2,000 additional shares on June 17, 2026 at an average price of $699.00 per share. After these transactions, he directly owns 4,880 shares of common stock and 3,000 options to purchase common stock, and indirectly reports 133 shares held in a custody account for a child and 267 shares held in a children's trust.
Peter W. Getsinger filed a Form 144 proposing sales of Common stock. The notice lists an intended sale of 2,000 shares (exercise of options under a registered plan dated 04/01/2026) and reports actual sales in the past three months of 4,728, 3,000 and 2,581 shares on 06/16/2026, 04/29/2026 and 04/02/2026, respectively, with corresponding proceeds reported.
The transactions are reported through Morgan Stanley Smith Barney LLC as broker/dealer. The filing is a regulatory notice of proposed and recent dispositions; cash‑flow treatment is shown as cash for the exercise and specific proceeds are listed for the past sales.
AGX submitted a Form 144 notice reporting a proposed sale of 760 shares and related equity activity. The filing lists an option exercise for 455 shares on 06/17/2026, a restricted stock issuance of 305 shares on 04/17/2026, and a reported sale of 600 shares by Joshua Baugher on 04/16/2026 for $363,360.
ARGAN INC director Cynthia Flanders reported an open-market sale of 2,596 shares of the company’s common stock. The trade took place on June 15, 2026 at a price of $666.31 per share. Following this transaction, she directly holds 23,144 common shares.
ARGAN INC president and CEO David Hibbert Watson reported a mix of stock sales and option exercises in company shares. On June 15, 2026, he sold 9,993 common shares in open-market trades at an average price of $651.22 per share. On June 16, 2026, he sold a further 1,880 shares at an average price of $707.35 per share and exercised stock options covering a total of 3,333 shares at exercise prices of $39.47, $61.22, and $148.72 per share using the net settle method. The filing reflects both profit-taking sales and increased direct ownership from option exercises.
ARGAN INC director-associated entity sells shares in an open-market transaction. On June 12, 2026, an entity associated with director William F. Griffin Jr., identified as William F Griffin Jr GRAT II dtd Oct 6, 2025, sold 50,000 shares of Argan common stock at an average price of $643.46 per share. Following this sale, the GRAT continued to hold 90,976 Argan shares indirectly for Griffin.
AGX files a notice of proposed sale of 4,728 shares of Common Stock related to the exercise of options under a registered plan dated 06/16/2026. The filing lists prior sales by Peter W. Getsinger of 3,000 shares on 04/29/2026 and 2,581 shares on 04/02/2026, with cash consideration noted for the exercise.
David Watson submitted a notice under Rule 144 relating to proposed sales of Common Stock of AGX. The filing lists a planned equity grant/exercise of 1,880 shares on 06/16/2026 and reports shares sold in the past three months of 9,993 shares on 06/15/2026 and 19,310 shares on 04/17/2026.